Lapatinib

Lapatinib is a small-molecule kinase inhibitor that targets the epidermal growth factor receptor and the human epidermal growth factor receptor 2 (HER2). In March 2007, lapatinib distosylate monohydrate (Tykerb; GlaxoSmithKline) was approved by the FDA for the treatment of patients with advanced or...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature reviews. Drug discovery 2007-06, Vol.6 (6), p.431-432
Hauptverfasser:	Moy, Beverly, Kirkpatrick, Peter, Kar, Santwana, Goss, Paul
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - therapeutic use Biomedical and Life Sciences Biomedicine Biotechnology Blood-Brain Barrier Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - pathology Cancer Research Complications and side effects Diagnosis Drug therapy Female fresh-from-the-pipeline Health aspects Humans Medicinal Chemistry Molecular Medicine Pharmacology/Toxicology Quinazolines - pharmacokinetics Quinazolines - pharmacology Quinazolines - therapeutic use Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, ErbB-2 - antagonists & inhibitors Risk factors Women
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Lapatinib is a small-molecule kinase inhibitor that targets the epidermal growth factor receptor and the human epidermal growth factor receptor 2 (HER2). In March 2007, lapatinib distosylate monohydrate (Tykerb; GlaxoSmithKline) was approved by the FDA for the treatment of patients with advanced or metastatic breast cancer whose tumours overexpress HER2 and who have received prior therapy including an anthracycline, a taxane and trastuzumab. Lapatinib
ISSN:	1474-1776 1474-1784
DOI:	10.1038/nrd2332